

Tuomas Mirtti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7398896/tuomas-mirtti-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

842
citations

15
h-index

28
g-index

78
ext. papers

1,167
ext. citations

5.6
avg, IF

3.77
L-index

#	Paper	IF	Citations
65	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma.. <i>Oncolmmunology</i> , 2022 , 11, 1993042	7.2	0
64	Spectral decoupling for training transferable neural networks in medical imaging.. <i>IScience</i> , 2022 , 25, 103767	6.1	
63	Stromal FAP Expression is Associated with MRI Visibility and Patient Survival in Prostate Cancer. <i>Cancer Research Communications</i> , 2022 , 2, 172-181		0
62	AI Model for Prostate Biopsies Predicts Cancer Survival. <i>Diagnostics</i> , 2022 , 12, 1031	3.8	
61	Abstract PR016: The spatial landscape of clonal somatic mutations in benign and malignant tissue. <i>Cancer Research</i> , 2022 , 82, PR016-PR016	10.1	
60	Characteristics of Patients in SPCG-15A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. <i>European Urology Open Science</i> , 2022 , 41, 63-73	0.9	
59	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Non-organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. <i>European Urology Focus</i> , 2021 , 7, 1316-1323	5.1	3
58	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.. <i>BJU International</i> , 2021 ,	5.6	1
57	Response to Letter on use of functional imaging by 11C-metomidate PET for primary aldosteronism subtyping. <i>European Journal of Endocrinology</i> , 2021 , 184, L11-L12	6.5	0
56	Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers. <i>Prostate</i> , 2021 , 81, 368-376	4.2	1
55	Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli ex vivo. <i>Diabetologia</i> , 2021 , 64, 1866-1879	10.3	4
54	Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. <i>Scientific Reports</i> , 2021 , 11, 13684	4.9	0
53	Three-Dimensional Presentation of Tumor Histopathology: A Model Using Tongue Squamous Cell Carcinoma. <i>Diagnostics</i> , 2021 , 11,	3.8	2
52	Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	3
51	Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 448-454	1.6	0
50	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. <i>Oncolmmunology</i> , 2020 , 9, 1761229	7.2	9
49	PTEN and ERG expression in MRI-ultrasound guided fusion biopsy correlated with radical prostatectomy findings in men with prostate cancer. <i>Prostate</i> , 2020 , 80, 1118-1127	4.2	2

48	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. <i>PLoS ONE</i> , 2020 , 15, e0235779	3.7	2
47	Functional imaging with 11C-metomidate PET for subtype diagnosis in primary aldosteronism. <i>European Journal of Endocrinology</i> , 2020 , 183, 539-550	6.5	13
46	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials). <i>Journal of Magnetic Resonance Imaging</i> , 2020 , 51, 1556-1567	5.6	15
45	Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets. <i>International Journal of Medical Informatics</i> , 2020 , 133, 104014	5.3	6
44	Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study. <i>Cancer Imaging</i> , 2020 , 20, 72	5.6	0
43	Fast prostate retrieval in robot-assisted laparoscopic prostatectomy for next-generation biobanking. <i>Journal of Robotic Surgery</i> , 2020 , 14, 271-274	2.9	1
42	Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 231-246	6.1	4
41	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy 2020 , 15, e0235779		
40	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy 2020 , 15, e0235779		
39	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy 2020 , 15, e0235779		
38	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy 2020 , 15, e0235779		
37	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. <i>PLoS Medicine</i> , 2019 , 16, e1002813	11.6	25
36	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. <i>International Journal of Cancer</i> , 2019 , 144, 1356-1366	7.5	15
35	Tumor expression of human chorionic gonadotropin beta mRNA and prognosis of prostate cancer treated by radical prostatectomy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2019 , 79, 424-430	2	
34	Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. <i>Prostate</i> , 2019 , 79, 1505-1513	4.2	14
33	The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 221-221	2.2	1
32	Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1642-1651	4	5
31	Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. <i>FASEB Journal</i> , 2019 , 33, 2858-2869	0.9	34

30	New prostate cancer grade grouping system predicts survival after radical prostatectomy. <i>Human Pathology</i> , 2018 , 75, 159-166	3.7	13
29	ITGB1-dependent upregulation of Caveolin-1 switches TGF β signalling from tumour-suppressive to oncogenic in prostate cancer. <i>Scientific Reports</i> , 2018 , 8, 2338	4.9	15
28	PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance. <i>European Urology Focus</i> , 2018 , 4, 867-873	5.1	24
27	Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 103-115	6.7	10
26	Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy. <i>Oncotarget</i> , 2018 , 9, 31200-31213	3.3	12
25	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 313-320	1.6	25
24	Patient Experience of Systematic Versus Fusion Prostate Biopsies. <i>European Urology Oncology</i> , 2018 , 1, 202-207	6.7	11
23	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. <i>European Urology Oncology</i> , 2018 , 1, 268-275	6.7	3
22	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017 , 71, 319-327	10.2	50
21	Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? <i>Eur Urol</i> . 2017;71:838-40. <i>European Urology</i> , 2017 , 72, e68-e69	10.2	
20	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. <i>Scientific Reports</i> , 2017 , 7, 12682	4.9	7
19	A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. <i>European Journal of Epidemiology</i> , 2017 , 32, 521-527	12.1	16
18	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology</i> , 2017 , 18, 132-142	21.7	90
17	Metabolomic Profiling of Extracellular Vesicles and Alternative Normalization Methods Reveal Enriched Metabolites and Strategies to Study Prostate Cancer-Related Changes. <i>Theranostics</i> , 2017 , 7, 3824-3841	12.1	116
16	Repeat multiparametric MRI in prostate cancer patients on active surveillance. <i>PLoS ONE</i> , 2017 , 12, e0189272	3.7	17
15	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. <i>Modern Pathology</i> , 2016 , 29, 1565-1574	9.8	32
14	Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. <i>Scientific Reports</i> , 2016 , 6, 36161	4.9	2
13	Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0153745	3.7	13

12	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016 , 2, 101-109	1	22
11	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016 , 2, 263-272	1	6
10	Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. <i>International Journal of Cancer</i> , 2016 , 139, 140-52	7.5	14
9	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. <i>Scandinavian Journal of Urology</i> , 2016 , 50, 380-6	1.6	9
8	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. <i>PLoS ONE</i> , 2015 , 10, e0133552	3.7	39
7	Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 16.e1-16.e7	2.8	4
6	Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 713-26	6.1	13
5	Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion. <i>Developmental Cell</i> , 2015 , 32, 318-34	10.2	64
4	Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. <i>PLoS ONE</i> , 2015 , 10, e0140671	3.7	22
3	Correlation of endothelial angiopoietin-2 expression with tumor angiogenesis and response to sunitinib in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 461-461	2.2	
2	Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. <i>Human Pathology</i> , 2013 , 44, 310-9	3.7	32
1	The spatial landscape of clonal somatic mutations in benign and malignant tissue		1